Cas:91748-18-4 methyl 2-[4-(trifluoromethyl)phenyl]benzoate manufacturer & supplier

Chemical Name:methyl 2-[4-(trifluoromethyl)phenyl]benzoate

CAS.NO:91748-18-4

Synonyms:4′-Trifluoromethyl-biphenyl-2-carboxylic acid methyl ester;4′-Trifluoromethyl-biphenyl-2-carboxylic acid;4′-trifluoromethyl-2-biphenylcarboxylic acid methyl ester

Molecular Formula:C₁₅H₁₁F₃O₂

Molecular Weight:280.24200

HS Code:2916399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:26.30000

Exact Mass:280.07100

LogP:4.15900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4′-Trifluoromethyl-biphenyl-2-carboxylic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4′-trifluoromethyl-2-biphenylcarboxylic acid methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4′-trifluoromethyl-2-biphenylcarboxylic acid methyl ester Use and application,4′-trifluoromethyl-2-biphenylcarboxylic acid methyl ester technical grade,usp/ep/jp grade.

Related News: Under the plan, nonessential hospital staff members who belong to the union would not go to work on Monday. methyl 2-[4-(trifluoromethyl)phenyl]benzoate manufacturer The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. methyl 2-[4-(trifluoromethyl)phenyl]benzoate supplier Under the plan, nonessential hospital staff members who belong to the union would not go to work on Monday. methyl 2-[4-(trifluoromethyl)phenyl]benzoate vendor The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk. methyl 2-[4-(trifluoromethyl)phenyl]benzoate factory In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.